

[133] CANCER AND THYROID - A NOVEL ONCOLOGICAL APPROACH

Offer Fabian¹, ¹ Musli Thyropeutics Ltd.

- **Investment Rational**
Musli Thyropeutics offers a novel cancer treatment for GBM, brain metastases, and other aggressive cancers. With the Phase III trial initiating in 2018, Musli is positioned to enter a multi-billion market by 2022, with limited investment. Effort is led by our team of experts, former Novartis, Medtronic, Merck and Teva executives who brought numerous drugs to market.
- **Business Strategy**
Musli presents numerous case studies of treated patients with outstanding results. Our drug combination is already patented in the US and other key territories, and was granted orphan designation by the FDA for GBM. Our goal is to leverage the very short 505B2 path to market and launch Musli in the US by 2022 with a total investment under \$25M.
- **Core Technology**
Musli's patented technology for drug combination inducing hypothyroxinemia for treating cancer. This novel therapeutic approach evolved from anecdotal observations and cases showing significant benefit to patients. The well-established safety record of Musli's APIs allows Musli to pursue superiority while relying on existing safety data. Today, non-genomic actions of thyroid hormones are well understood and being transformed into interventions.
- **Product Profile/Pipeline**
Musli is initially targeting glioblastoma with an annual multi-billion dollar market in the USA alone. Our next sought indications are brain metastases representing an even greater USA market potential. The Musli combination demonstrated efficacy anecdotally in additional cancers, including ovarian, pancreatic, breast, and lung cancers. These indications form additional potential multi-billion dollar markets.

What's Next?

Musli's team is working towards IND submission and the subsequent initiation of a Phase III pivotal trial in 2018. We expect completing GMP batch manufacturing by Q2 2018, and concurrently finalize our dialogue with FDA. To accomplish this, Musli will raise \$3.5M by mid-2017, and an additional amount of \$5-10M towards trial initiation in mid-2018.